Novartis’ Japan unit, Novartis Pharma, saw its sales soar sharply in 2019 after the integration of Alcon Pharma in April last year, with its revenue reaching 330.5 billion yen versus 263.2 billion yen in the previous year. The figure was…
To read the full story
Related Article
- EquMet Becomes Best Seller for Novartis Japan in FY2018
April 4, 2019
- Alcon Pharma to Be Integrated into Novartis Japan in April
March 6, 2019
BUSINESS
- Asahi Kasei Pharma to Rebrand as Asahi Kasei Therapeutics in April
March 6, 2026
- Keytruda Maintains Top Spot for 29 Straight Months in February: Encise
March 6, 2026
- Takeda Files Japan NDA for Narcolepsy Drug Oveporexton
March 5, 2026
- Kyowa Kirin Sticks to Long-Term Targets despite Rocatinlimab Setback
March 5, 2026
- Ono Partners with Congruence on Neurology, Immunology Drug Discovery
March 5, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





